Biofrontera Inc. to Report Second Quarter FY 2025 Financial Results on August 13, 2025

GlobeNewswire

05 Aug

Woburn, MA, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc., (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results for the three and six months ended June 30, 2025 on Wednesday, August 13, 2025. The results will be released after the market close on Wednesday, August 13 and the company will host a conference call on Thursday, August 14 at 10:00am Eastern Time.

Conference Call and Webcast Information

Event:	Biofrontera Inc. Second Quarter 2025 Financial Results and Business Update Conference Call
Date:	Thursday, August 14, 2025
Time:	10:00am ET
Conference Call:	1-877-877-1275 (U.S.) 1-412-858-5202 (international)
Webcast:	Webcast \| Second Quarter 2025 Financial Results and Business Update Conference Call

About Biofrontera Inc.

Biofrontera Inc. is a U.S.-based biopharmaceutical company specializing in the development and treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz ^® with the RhodoLED ^® lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. The Company performs clinical trials to extend the use of the products to treat non-melanoma skin cancers and moderate to severe acne. For more information, visit www.biofrontera-us.com and follow Biofrontera on LinkedIn and X.

Contacts:
Investor Relations
Andrew Barwicki
1-516-662-9461
ir@bfri.com

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2557335493"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2557335493\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2557335493?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-05 02:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557335493","market":"hk","top_or_hot":-1,"title":"Biofrontera Inc. to Report Second Quarter FY 2025 Financial Results on August 13, 2025","media":"GlobeNewswire","content":"<html><body><p><strong>Woburn, MA, Aug.  04, 2025  (GLOBE NEWSWIRE) -- <a href=\"https://laohu8.com/S/BFRI\">Biofrontera Inc</a>., (<a href=\"https://laohu8.com/S/NDAQ\">Nasdaq</a>:BFRI) (\"Biofrontera\" or the \"Company\")</strong>, a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results for the three and six months ended June 30, 2025 on Wednesday, August 13, 2025. The results will be released after the market close on Wednesday, August 13 and the company will host a conference call on Thursday, August 14 at 10:00am <a href=\"https://laohu8.com/S/EML\">Eastern</a> Time.</p> <p><strong>Conference Call and Webcast <a href=\"https://laohu8.com/S/III\">Information</a></strong></p> <table><tr><td>Event:</td><td>Biofrontera Inc. Second Quarter 2025 Financial Results and Business Update Conference Call</td></tr><tr><td>Date:</td><td>Thursday, August 14, 2025</td></tr><tr><td>Time:</td><td>10:00am ET</td></tr><tr><td>Conference Call:</td><td>1-877-877-1275 (U.S.)<br/>1-412-858-5202 (international)</td></tr><tr><td>Webcast:</td><td>Webcast | Second Quarter 2025 Financial Results and Business Update Conference Call</td></tr><tr><td> </td><td> </td></tr></table> <p><strong>About Biofrontera Inc.</strong></p> <p>Biofrontera Inc. is a U.S.-based biopharmaceutical company specializing in the development and treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz <sup>®</sup> with the RhodoLED <sup>®</sup> lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. The Company performs clinical trials to extend the use of the products to treat non-melanoma skin cancers and moderate to severe acne. For more information, visit www.biofrontera-us.com and follow Biofrontera on <a href=\"https://laohu8.com/S/LNKD\">LinkedIn</a> and X.</p> <p>Contacts:<br/>Investor Relations<br/>Andrew Barwicki<br/>1-516-662-9461<br/>ir@bfri.com</p> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/NjNjZDU1OGQtNmY5Mi00MjMxLThjNDAtOGRlZWZmNTMzNjI4LTUwMDA4NTk2My0yMDI1LTA4LTA0LWVu/tiny/Biofrontera-Inc-.png\"/></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biofrontera Inc. to Report Second Quarter FY 2025 Financial Results on August 13, 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiofrontera Inc. to Report Second Quarter FY 2025 Financial Results on August 13, 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1016364462\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">GlobeNewswire </p>\n<p class=\"h-time\">2025-08-05 02:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p><strong>Woburn, MA, Aug.  04, 2025  (GLOBE NEWSWIRE) -- <a href=\"https://laohu8.com/S/BFRI\">Biofrontera Inc</a>., (<a href=\"https://laohu8.com/S/NDAQ\">Nasdaq</a>:BFRI) (\"Biofrontera\" or the \"Company\")</strong>, a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results for the three and six months ended June 30, 2025 on Wednesday, August 13, 2025. The results will be released after the market close on Wednesday, August 13 and the company will host a conference call on Thursday, August 14 at 10:00am <a href=\"https://laohu8.com/S/EML\">Eastern</a> Time.</p> <p><strong>Conference Call and Webcast <a href=\"https://laohu8.com/S/III\">Information</a></strong></p> <table><tr><td>Event:</td><td>Biofrontera Inc. Second Quarter 2025 Financial Results and Business Update Conference Call</td></tr><tr><td>Date:</td><td>Thursday, August 14, 2025</td></tr><tr><td>Time:</td><td>10:00am ET</td></tr><tr><td>Conference Call:</td><td>1-877-877-1275 (U.S.)<br/>1-412-858-5202 (international)</td></tr><tr><td>Webcast:</td><td>Webcast | Second Quarter 2025 Financial Results and Business Update Conference Call</td></tr><tr><td> </td><td> </td></tr></table> <p><strong>About Biofrontera Inc.</strong></p> <p>Biofrontera Inc. is a U.S.-based biopharmaceutical company specializing in the development and treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz <sup>®</sup> with the RhodoLED <sup>®</sup> lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. The Company performs clinical trials to extend the use of the products to treat non-melanoma skin cancers and moderate to severe acne. For more information, visit www.biofrontera-us.com and follow Biofrontera on <a href=\"https://laohu8.com/S/LNKD\">LinkedIn</a> and X.</p> <p>Contacts:<br/>Investor Relations<br/>Andrew Barwicki<br/>1-516-662-9461<br/>ir@bfri.com</p> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/NjNjZDU1OGQtNmY5Mi00MjMxLThjNDAtOGRlZWZmNTMzNjI4LTUwMDA4NTk2My0yMDI1LTA4LTA0LWVu/tiny/Biofrontera-Inc-.png\"/></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.globenewswire.com/news-release/2025/08/04/3126787/0/en/Biofrontera-Inc-to-Report-Second-Quarter-FY-2025-Financial-Results-on-August-13-2025.html","article_id":"2557335493","we_media_id":"1016364462","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2557335493","pubTimestamp":1754330400,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"GlobeNewswire","introduction":"Share your news with media, investors, and consumers with targeted distribution options from one of the world’s largest and most trusted newswires.","home_visible":1,"id":"1016364462","head_image":"https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a"},"summary":"Woburn, MA, Aug.  04, 2025  (GLOBE NEWSWIRE) -- Biofrontera Inc., (Nasdaq:BFRI) (\"Biofrontera\" or the \"Company\"), a biopharmaceutical company specializing in the commercialization of dermatological pr","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","BFRI":"Biofrontera Inc"},"translate_title":"Biofrontera Inc.将于2025年8月13日报告2025财年第二季度财务业绩","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BFRI":1},"content_text":"Woburn, MA, Aug.  04, 2025  (GLOBE NEWSWIRE) -- Biofrontera Inc., (Nasdaq:BFRI) (\"Biofrontera\" or the \"Company\"), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results for the three and six months ended June 30, 2025 on Wednesday, August 13, 2025. The results will be released after the market close on Wednesday, August 13 and the company will host a conference call on Thursday, August 14 at 10:00am Eastern Time. Conference Call and Webcast Information Event:Biofrontera Inc. Second Quarter 2025 Financial Results and Business Update Conference CallDate:Thursday, August 14, 2025Time:10:00am ETConference Call:1-877-877-1275 (U.S.)1-412-858-5202 (international)Webcast:Webcast | Second Quarter 2025 Financial Results and Business Update Conference Call   About Biofrontera Inc. Biofrontera Inc. is a U.S.-based biopharmaceutical company specializing in the development and treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz ® with the RhodoLED ® lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. The Company performs clinical trials to extend the use of the products to treat non-melanoma skin cancers and moderate to severe acne. For more information, visit www.biofrontera-us.com and follow Biofrontera on LinkedIn and X. Contacts:Investor RelationsAndrew Barwicki1-516-662-9461ir@bfri.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}